Recognizing sustained switches between the two diseases can prevent premature discontinuation of effective biologics and point toward Janus kinase inhibitors, a 148-patient cohort suggests.
Analyses by treatment timing, cumulative dose, and stunting supported the overall finding, though early-initiation and female subgroup data were limited.